All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2019-06-06T10:30:35.000Z

Turning the corner on R/R CNS lymphoma: applying precision and immune-based treatments

Jun 6, 2019
Share:

Bookmark this article

Lakshmi Nayak, Dana Farber Institute, talks about applying precision and immune-based treatments to patients with relapsed/refractory central nervous system (R/R CNS) lymphoma. Dr. Nayak discusses the significant advances in the treatment of R/R CNS lymphoma, however, explains that relapses and reoccurrences continue in about 50% of patients. Additionally, Dr. Nayak explains that about one-third of patients are refractory to the primary initial therapy, for this reason, there is an unmet need for primary R/R CNS lymphoma.

Turning the corner on R/R CNS lymphoma: applying precision and immune-based treatments

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox